PhII Alzheimer's failure deals new blow to Roche, AC Immune — but the tau hypothesis is far from dead
The leading anti-tau antibody has failed its first Phase II testing, casting a shadow on a popular target (just trailing amyloid beta) for Alzheimer’s disease.
Roche and AC Immune are quick to acknowledge disappointment in the topline readout, which suggested that semorinemab did not reduce cognitive decline among patients with early Alzheimer’s disease, who are either just starting to have symptoms or have mild manifestations.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,200+ biopharma pros reading Endpoints daily — and it's free.